Atossa Therapeutics reports progress in breast cancer treatments
SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company with a market capitalization of $120 million and an impressive 13% gain over the past week, has announced significant advancements in their clinical programs for breast cancer treatment and prevention.